FLT3 mutation assay laboratory cross validation: results from the CALGB 10603/RATIFY(Alliance) trial in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
      Google Scholar   
Citation:
Blood vol 132 (Suppl) 2800
Meeting Instance:
ASH 2018
Year:
2018
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3235  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171  
Corr. Author:
 
Authors:
                                     
Networks:
LAPS-IL057, LAPS-MA036, LAPS-OH007   
Study
CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: